TOKYOâ€”Otsuka Pharmaceutical Co. agreed to buy Avanir Pharmaceuticals Inc. of the U.S. for $3.5 billion, the latest large deal by a Japanese drug maker looking to expand overseas.. The deal gives Otsuka, maker of the schizophrenia and depression drug Abilify, access to more treatments for central-nervous-system diseases. California-based Avanir sells Nuedexta, a treatment for a condition known as pseudobulbar affect that causes sudden and involuntary outbursts in patients with neurological diseases such as amyotrophic lateral...
  